Fig. 4
RDS dosage-dependent inactivation of the infectivity of SARS-CoV-2 and derived Ha-CoV-2 variants. A SARS-CoV-2 particles were incubated with serially diluted RDS at 37 °C for 1 h. Subsequently, the mixture were further serially diluted and added to Vero cells for plaque assays to determine reduction of virus infectivity. Inhibition assays were performed in triplicate, and statistical significance was determined using One-Way ANOVA with Dunnett’s Post Test in Prism 7 (Graph Pad). Significance values are indicated using asterisks as follows; *p < 0.02. The designation "ns" stands for "not significant". B Ha-CoV-2(Luc) and related S protein variants were incubated with serially diluted RDS at 37 °C for 1 h. Subsequently, the mixture were used to infect HEK293T (ACE2/TMPRESS2) target cells. Inhibition of viral infection was quantified at 12 h post infection by luciferase assay. The IC50 values of RDS were calculated to be at dilutions of 1:177 (wt), 1:828 (B.1.1.7), 1:124 (B.1.351), 1:88 (P.1), 1:134 (B.1.1.207), 1:2601 (B.1.1.298), 1:70 (B.1.258), 1:362 (B.1.429), 1:163 (B.1.494), 1:137 (B.1.2)